Manhattan Institute for Policy Research.
search  
 
Subscribe   Subscribe   MI on Facebook Find us on Twitter Find us on Instagram      
 
 
   
 
     
Andrew C. von Eschenbach.
HIGH-RES PHOTO
FOLLOW
ISSUES:
Medicare / Medicaid
Consumer-Driven Health Care
By von Eschenbach:
ARTICLES/OP-EDS
RESEARCH
CONTACT:
Katherine Lazarski,
Press Officer, Communications
646-839-3313
TOPICAL INDEX:
MI Publications &
City Journal Articles:
SCHOLARS INDEX:
Andrew von Eschenbach

Andrew C. von Eschenbach is chairman of the Manhattan Institute’s Project FDA. In 2005–09, he was commissioner of the U.S. Food and Drug Administration, where he championed an agenda to modernize the FDA. Von Eschenbach joined the FDA after four years as director of the National Cancer Institute (NCI) at the National Institutes of Health, where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum. At the time of his appointment by President Bush to serve as director of NCI, he was president-elect of the American Cancer Society. Von Eschenbach entered government service after more than three decades as a surgeon, oncologist, and executive, including numerous leadership roles, from chairman of the department of urologic oncology to executive vice president and chief academic, at the University of Texas M. D. Anderson Cancer Center in Houston.

Author of more than 300 scientific articles and studies, von Eschenbach was a founding member of the National Dialogue on Cancer. In 2006, he was named one of Time’s “100 Most Influential People to Shape the World”; in 2007 and 2008, he was selected as one of Modern Healthcare / Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.”

Von Eschenbach holds a B.S. from St. Joseph’s University and an M.D. from Georgetown University School of Medicine. Early in his career, he was a lieutenant commander in the U.S. Navy Medical Corps. After completing a residency in urologic surgery at Pennsylvania Hospital, von Eschenbach was an instructor in urology at the University of Pennsylvania School of Medicine.


[SORT BY CATEGORY] [SORT BY PUBLICATION TYPE]

Business and Economy
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13
  • An Rx For Making Wonder Drugs The Boston Herald, 08-24-14


  • Economic Development
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13


  • FDA Reform
  • Toward a 21st-Century FDA Wall Street Journal, 04-15-12
  • FDA Approvals Are a Matter of Life and Death Wall Street Journal, 06-17-12
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13
  • An Rx For Making Wonder Drugs The Boston Herald, 08-24-14
  • How To Upgrade Ebola Fight USA Today, 11-19-14
  • 21st Century Cures Legislation: Embracing The Future Of Medicine The Morning Consult, 06-15-15


  • Government Reform
  • How To Upgrade Ebola Fight USA Today, 11-19-14


  • Healthcare
  • Eliminating the Suffering and Death Due to Cancer by 2015 Medical Progress Bulletin, September 2005
  • Medical Innovation: How the U.S. Can Retain Its Lead Wall Street Journal, 02-14-12
  • Paul Howard interviews new Project FDA chairman, Dr. von Eschenbach about his Wall Street Journal op-ed, “Medical Innovation: How the U.S. Can Retain Its Lead.” Podcast: Interview, February 23, 2012
  • Paul Howard interviews Frmr FDA Commissioner Andrew von Eschenbach about post-market efficacy and the future of FDA. Podcast: Interview, February 23, 2012
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13
  • An Rx For Making Wonder Drugs The Boston Herald, 08-24-14
  • 21st Century Cures Legislation: Embracing The Future Of Medicine The Morning Consult, 06-15-15


  • National Politics
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13
  • How To Upgrade Ebola Fight USA Today, 11-19-14
  • 21st Century Cures Legislation: Embracing The Future Of Medicine The Morning Consult, 06-15-15


  • Regulation
  • How To Upgrade Ebola Fight USA Today, 11-19-14


  • Value of Medicine
  • FDA Reform Can Lift U.S. Economy Bloomberg, 02-28-13


  •  

     

     
     
     

    The Manhattan Institute, a 501(c)(3), is a think tank whose mission is to develop and disseminate new ideas
    that foster greater economic choice and individual responsibility.

    Copyright © 2015 Manhattan Institute for Policy Research, Inc. All rights reserved.

    52 Vanderbilt Avenue, New York, N.Y. 10017
    phone (212) 599-7000 / fax (212) 599-3494